Scholarlink

Purpose <p>There is a lack of safety and efficacy data for newer biologic agents among adults ≥ 60&#xa0;years old with inflammatory bowel disease (IBD) given their limited inclusion in clinical trials. We conducted a retrospective cohort study comparing the safety and efficacy of ustekinumab (UST) or vedolizumab (VDZ) use in older adults as compared to younger adults with IBD.</p> Methods <p>This single-center retrospective study compared individuals 18 to 59&#xa0;years old to individuals ≥ 60&#xa0;years old with a confirmed diagnosis of IBD who began VDZ or UST treatment between 2014 and 2022. The primary efficacy and safety outcomes were endoscopic remission and serious infection, respectively. Secondary outcomes included endoscopic response, clinical remission, and non-severe adverse events. Multivariable regression was used to identify factors independently associated with safety and efficacy.</p> Results <p>Overall, 948 individuals were included, with 779 (82.2%) &lt; 60&#xa0;years-old. In total, 548 (57.8%) had Crohn’s disease, 367 (38.7%) had ulcerative colitis, 33 (3.5%) had indeterminate colitis, and a total of 403 individuals (42.5%) initiated VDZ whereas 545 (57.5%) initiated UST. When assessing efficacy, younger and older individuals had comparable rates of endoscopic remission (&lt; 60&#xa0;years-old 27.5% vs 29.0% ≥ 60&#xa0;years-old, p = 0.69) as well as clinical remission (&lt; 60&#xa0;years-old 26.4% vs 26.6% ≥ 60&#xa0;years-old, p = 0.96). When assessing safety, serious infection rates (&lt; 60&#xa0;years-old 8.9% vs 8.9% ≥ 60&#xa0;years-old, <i>p</i>  = 0.99) and non-severe adverse event rates (&lt; 60&#xa0;years-old 12.3% vs 8.9% ≥ 60&#xa0;years-old, <i>p</i> = 0.21) were not significantly different. On multivariable analysis, measures of disease severity (prior advanced therapy use, prior corticosteroid use, severe disease) significantly decreased the odds of endoscopic and clinical remission. Additionally, prior advanced therapy use and the presence of comorbidities increased the odds of serious infections.</p> Conclusion <p>The use of UST and VDZ had similar efficacy and safety outcomes in older adults as compared to younger individuals with IBD. Decisions to utilize these biologics should be driven by overall disease burden and comorbidities, and not be deferred due to advanced chronological age alone. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults with Inflammatory Bowel Disease

  • 期刊论文

  • 发表日期：

    2025年9月16日

查看全文
  • Moniyka Sachar,
  • Pakdee Rojanasopondist,
  • William Beaty,
  • Cristina Fernandez,
  • Olivia Delau,
  • Alice Li,
  • Nicole Werner,
  • Polly Kirsch,
  • Rebecca Minerva Ortiz,
  • Xinyu Wang,
  • Megan Murphy,
  • Jordan Eric Axelrad,
  • Simon Hong,
  • Ariela Holmer,
  • Shannon Chang,
  • David Hudesman,
  • Seymour Katz,
  • Lisa Malter,
  • Adam S. Faye

摘要

Purpose

There is a lack of safety and efficacy data for newer biologic agents among adults ≥ 60 years old with inflammatory bowel disease (IBD) given their limited inclusion in clinical trials. We conducted a retrospective cohort study comparing the safety and efficacy of ustekinumab (UST) or vedolizumab (VDZ) use in older adults as compared to younger adults with IBD.

Methods

This single-center retrospective study compared individuals 18 to 59 years old to individuals ≥ 60 years old with a confirmed diagnosis of IBD who began VDZ or UST treatment between 2014 and 2022. The primary efficacy and safety outcomes were endoscopic remission and serious infection, respectively. Secondary outcomes included endoscopic response, clinical remission, and non-severe adverse events. Multivariable regression was used to identify factors independently associated with safety and efficacy.

Results

Overall, 948 individuals were included, with 779 (82.2%) < 60 years-old. In total, 548 (57.8%) had Crohn’s disease, 367 (38.7%) had ulcerative colitis, 33 (3.5%) had indeterminate colitis, and a total of 403 individuals (42.5%) initiated VDZ whereas 545 (57.5%) initiated UST. When assessing efficacy, younger and older individuals had comparable rates of endoscopic remission (< 60 years-old 27.5% vs 29.0% ≥ 60 years-old, p = 0.69) as well as clinical remission (< 60 years-old 26.4% vs 26.6% ≥ 60 years-old, p = 0.96). When assessing safety, serious infection rates (< 60 years-old 8.9% vs 8.9% ≥ 60 years-old, p  = 0.99) and non-severe adverse event rates (< 60 years-old 12.3% vs 8.9% ≥ 60 years-old, p = 0.21) were not significantly different. On multivariable analysis, measures of disease severity (prior advanced therapy use, prior corticosteroid use, severe disease) significantly decreased the odds of endoscopic and clinical remission. Additionally, prior advanced therapy use and the presence of comorbidities increased the odds of serious infections.

Conclusion

The use of UST and VDZ had similar efficacy and safety outcomes in older adults as compared to younger individuals with IBD. Decisions to utilize these biologics should be driven by overall disease burden and comorbidities, and not be deferred due to advanced chronological age alone.